Ramicomp Genericon 5 mg/25 mg tablete
| Name | Ramicomp Genericon 5 mg/25 mg tablete |
|---|---|
| Marketing Authorisation Number | HR-H-669243429 |
| Active Substance | ramipril hidroklorotiazid |
| Composition | jedna tableta sadrži 5 mg ramiprila i 25 mg hidroklorotiazida |
| Pharmaceutical Form | tableta |
| Manufacturer | Genericon Pharma Gesellschaft m.b.H., Graz, Austrija Coripharma ehf., Hafnarfjoerdur, Island |
| Marketing Authorisation Holder | Genericon Pharma Gesellschaft m.b.H., Hafnerstraße 211, Graz, Austrija |
| Marketing Authorisation Date | 27.07.2020 |
| MA Period of Validity | unlimited |
| Classification Number | UP/I-530-09/18-02/212 |
| Registration Number | 381-12-01/38-20-03 |
| Prescription | na recept |
| Type of prescription | ponovljivi recept |
| Distribution | u ljekarni |
| Advertising to general public | zabranjeno |
| ATC Code | C09BA05 |
| Medicinal product marketed in the Croatia | Da |
| SmPC | download |
| PL | download |
Packaging
Direct Healthcare Professional Communication
| Name | Date | Download |
|---|---|---|
| Pismo zdravstvenim radnicima o riziku od nemelanomskog raka kože povezanog s primjenom hidroklorotiazida | 17.10.2018 | Alkaloid, Belupo, Berlin-Chemie Menarini, Boehringer Ingelheim International, Farmal, Genericon, Pharma, Jadran Galenski laboratorij, Krka - farma, Merck, Merck Sharp & Dohme, Novartis, PharmaSwiss, Pliva, Sandoz, sanofi-aventis i Stada |
